trending Market Intelligence /marketintelligence/en/news-insights/trending/qm7OaA5qpGIrh7Zh_x7SrA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Astellas Pharma's blood cancer drug gets US FDA fast track designation

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Astellas Pharma's blood cancer drug gets US FDA fast track designation

The U.S. Food and Drug Administration granted fast-track designation to Astellas Pharma Inc.'s gilteritinib to treat a certain type of blood cancer.

The designation covers the company's study of gilteritinib in adult patients with FLT3+ relapsed or refractory acute myeloid leukemia.

Astellas Pharma said four phase 3 trials of gilteritinib in various AML patient populations are underway.

Gilteritinib is an investigational compound discovered through a research collaboration between Astellas Pharma and Kotobuki Pharmaceutical Co. Ltd.

Astellas has exclusive global rights to the drug.